Relay Therapeutics Inc
RLAY8.920USD
+0.770+9.45%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.54BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Relay Therapeutics Inc Unternehmen
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Relay Therapeutics Inc Informationen
BörsenkürzelRLAY
Name des UnternehmensRelay Therapeutics Inc
IPO-datumJul 16, 2020
CEOPatel (Sanjiv K)
Anzahl der mitarbeiter261
WertpapierartOrdinary Share
GeschäftsjahresendeJul 16
Addresse60 Hampshire Street
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02139
Telefon16173708837
Websitehttps://relaytx.com/
BörsenkürzelRLAY
IPO-datumJul 16, 2020
CEOPatel (Sanjiv K)
Führungskräfte von Relay Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-19913.00%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
120.71K
-13038.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexis A. Borisy
Mr. Alexis A. Borisy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-19913.00%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
120.71K
-13038.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Tue, Nov 18
Aktualisiert: Tue, Nov 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
Andere
52.98%
Aktionäre
Aktionäre
Anteil
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
Andere
52.98%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
36.60%
Investment Advisor
27.59%
Private Equity
16.70%
Investment Advisor/Hedge Fund
12.95%
Research Firm
2.08%
Individual Investor
1.27%
Venture Capital
0.91%
Sovereign Wealth Fund
0.48%
Family Office
0.38%
Andere
1.05%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
457
170.34M
98.28%
-42.79M
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
SB Investment Advisers (UK) Limited
27.90M
16.1%
--
--
Sep 30, 2025
Commodore Capital LP
17.00M
9.81%
+3.65M
+27.34%
Sep 30, 2025
Point72 Asset Management, L.P.
14.77M
8.52%
+1.33M
+9.88%
Sep 30, 2025
Casdin Capital, LLC
11.34M
6.54%
-57.19K
-0.50%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.48M
6.05%
-143.98K
-1.35%
Sep 30, 2025
The Vanguard Group, Inc.
9.37M
5.4%
+15.89K
+0.17%
Sep 30, 2025
Bellevue Asset Management AG
8.35M
4.82%
+114.74K
+1.39%
Sep 30, 2025
Tang Capital Management, LLC
8.07M
4.65%
--
--
Sep 30, 2025
State Street Investment Management (US)
5.07M
2.92%
-136.80K
-2.63%
Sep 30, 2025
Nextech Invest, Ltd.
3.85M
2.22%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Tema Oncology ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
State Street SPDR S&P Biotech ETF
0.33%
ProShares Ultra Nasdaq Biotechnology
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Avantis US Small Cap Equity ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
iShares Biotechnology ETF
0.08%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.4%
Tema Oncology ETF
Anteil0.98%
ALPS Medical Breakthroughs ETF
Anteil0.51%
State Street SPDR S&P Biotech ETF
Anteil0.33%
ProShares Ultra Nasdaq Biotechnology
Anteil0.17%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.16%
Avantis US Small Cap Equity ETF
Anteil0.14%
Invesco Nasdaq Biotechnology ETF
Anteil0.12%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.09%
iShares Biotechnology ETF
Anteil0.08%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
